Document:

EX-10.45  BIO-CONCEPT LABORATORIES, INC. QUOTE

 

Exhibit 10.45

PROPRIETARY INFORMATION —CONFIDENTIAL

Sirion — 060724

PORTIONS OF THIS EXHIBIT MARKED “[* * *]” HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED, AND THE OMITTED PORTIONS HAVE BEEN FILED SEPARATELY IN PAPER FORM WITH THE SECURITIES AND
EXCHANGE COMMISSION.

Bio-Concept

Laboratories, Inc.

Quotation

Client:

Sirion Therapeutics, Inc. “CLIENT”

3110 Cherry Palm Drive, Suite 350

Tampa, FL 33619

Phone: (813) 496 7325

Fax: (813) 910-9585

Quote Number: Sirion — 060724                                                                                 Quote Date: 07/24/06

	 	 	 	 	 	 	 
	 	 	Payment	 	 	 	 
	Good Through	 	Terms	 	Bio-Concept Contact	 	Client Contact
	Valid 30 days

	 	[* * *]
	 	Scott Orphanos
	 	Bill Stringer

	 	 	 	 	 
	 	 	 	 	Estimated
	Activity	 	Activity Description	 	Cost
	Procurement of
Non- Standard
Materials

	 	Purchase, receive and release raw materials based on vendor certificate of
analysis. Additional testing requested will be quoted separately.
	 	[* * *]
	 
	 	 	 	 
	Ethylene Oxide
Sterilization (ETO)
of non-standard
containers
(performed off site)

	 	Package and ETO sterilize as sufficient number of units for the aseptic fill and
adoption to Bio-Concept’s validated cycle. Cost includes shipping, bioburden
testing, sterility verification with spore strips, and residual testing.
	 	[* * *]
	 
	 	 	 	 
	Process Development -

Sterilization

(Filtration)

	 	Filtration studies designed toward the selection of optimum type and minimum
surface area to volume ratio. This activity will describe the flow rate,
back-pressure, filter size, solution volume dependency. Perform bubble point test
against vendor specifications.
Write and issue report.
	 	[* * *]

N/A -Client to
provide filter
specifications
	 
	 	 	 	 
	Process Development -

Pilot Batch

	 	Prepare a scale-up batch using the proposed materials, compounding technique,
vessels, mixers, filters, containers and closures. Perform in-process testing and
finished product analyses to confirm suitability. Recommend any changes to
manufacturing procedure. Significant changes may require a second pilot batch at an
incremental charge.
	 	[* * *]
	 
	 	 	 	 
	Aseptic cGMP Clinical
Fill — Plastic Bottle
Standard Container and
Closure system
[* * *]

	 	Preparation and approval of master batch record
Approval of release specifications by client.
Plastic bottles, tips and caps (sufficient number for fills) provided by client;
release of materials on vendor Certificate of Analysis by Bio-Concept .
Purchase of small quantity (sufficient for fills) of necessary raw materials;
release on ID testing and vendor Certificate of Analysis
Manufacture up to [* * *] sterile units/batch
Submit executed batch record(s) to client for their release.
Includes a single standard packaging/shipping event to one U.S location. No release
testing will be performed
	 	[* * *]
	 
	 	 	 	 
	Labeling of
Manufactured Product

	 	Label up to [* * *] units of manufactured product. Activities include incorporating
the function into a batch record, generating standard labels, labeling product,
reconciling units. Randomization, safety seals, and boxing will be quoted
separately. Additional labeling requests will be charged at [* * *] per event.
	 	[* * *]
	 
	 	 	 	 
	Manufactured Product
and Retain Storage

	 	After [* * *], [* * *] per lot per condition per month unless combined with testing.	 	 

1

 

PROPRIETARY INFORMATION —CONFIDENTIAL

Sirion — 060724

Total Estimated Cost       [* * *]

[* * *]

	 	 	 	 	 
	Quote Generated By:	 	Client Acceptance:	 	 
	 
	Scott Orphanos
	 	 	 	 
	Executive Director,

	 	Client Signature:
	 	/s/ William Stringer
	 

	 	 	 	 
	Business Development

	 	Date: 8/10/06	 	 
	Phone: (888) 714-1900
	 	 	 	 
	Fax: (603) 437-4998	 	Purchase Order Number:
	 

	 	 	 	 

2

 

PROPRIETARY INFORMATION —CONFIDENTIAL

Sirion — 060724

General Terms & Conditions

	1.	 	Bio-Concept Laboratories, Inc. shall provide services in accordance with this Agreement.
Services are provided subject to the terms and conditions hereof, and such terms and
conditions may be modified only by written instrument signed by CLIENT and Bio-Concept
Laboratories, Inc. Provisions of any existing contract bet Bio-Concept Laboratories, Inc. and
CLIENT shall take precedence over any inconsistent terms and conditions of this order.
	 
	2.	 	CLIENT shall comply with all applicable laws and regulations relating to transmittal of
sample to Bio Concept. Bio-Concept will not be responsible for damages of any nature, which
may arise from returning used/unused samples to CLIENT.
	 
	3.	 	Bio-Concept makes no warranties with regard to the services to be performed hereunder,
including any expressed or implied warranties of merchantability or fitness for a particular
purpose of any work performed or information or products supplied by it. CLIENT is responsible
for reviewing Bio-Concept’s standard manufacturing processes/procedures to determine
suitability for specific manufacturing requirements. To the extent permitted by law, either
party’s liability, if any, for damages relating or arising out of this order shall be limited
to the fees paid or payable to Bio-Concept under this Agreement. Under no circumstances shall
either party be entitled to incidental, indirect, consequential or special damages under any
theory of law.
	 
	4.	 	Neither party shall have any liability to the other party for any failure to perform or delay
in performance if such failure is due to war, fire, flood, civil or labor unrest, government
action, or other contingencies beyond its reasonable control.
	 
	5.	 	No provision of this Agreement may be waived except by the express written consent of the
party waiving compliance. A waiver from time to time by either party of its rights or its
failure to exercise any remedy shall not operate or be construed as a continuing waiver of the
same or of any other of such party’s rights or remedies provided in this Agreement.

This Agreement is expires if not executed by the date indicated.

Each party, through its duly authorized officer, hereby accepts and agrees to the foregoing Agreement as

of this 10th day of August 2006.

          (Day)         (Month)

	 	 	 	 	 	 	 	 	 
	CLIENT	 	Bio-Concept Laboratories, Inc.	 	 
	 
	 	 	 	 	 	 	 	 
	By:

	 	/s/ William Stringer
	 	By:	 	 	 	 
	 

	 	 

	 	 	 	 

	 	 
	Title: VP Manufacturing & Compliance	 	Title:	 	 
	 

	 	 

	 	 	 	 

	 	 

3

 

PROPRIETARY INFORMATION —CONFIDENTIAL

Sirion — 060724

NOTES AND COMMENTS

	1.	 	All payments are required by the Due Date of the invoice. Payments not received by Bio-Concept within
this timeframe shall be assessed a finance charge of 3.0% per month of the amount invoiced for each
30 day period or fraction thereof that the payment is not received by Bio-Concept.
	 
	2.	 	Cost per event does not include the purchase of unique materials and/or unique chemicals,
special handling (as requested by the Client), packaging and shipping charges, and/or disposal
charges (see Note 3 of Notes and Comments for a breakdown of packaging, shipping and/or
disposal charges). All costs incurred as a result of the foregoing, except packaging, shipping
and/or disposal charges, will be charged at Bio-Concept’s cost plus a handling fee.
	 
	3.	 	Packaging, shipping and/or disposal charges to be paid by the Client to Bio-Concept as a
result of the Client’s request to ship raw material, in-process material and/or product,
and/or finished manufactured product are as follows:

	 	 	 	? Standard (ambient ground) — [* * *] per occurrence, per lot
plus carrier charge and handling fee.
	 
	 	 	 	? Non-standard (frozen or overnight) — [* * *] per occurrence,
per lot plus carrier charge and handling fee.
	 
	 	 	 	? Disposal — [* * *] per occurrence, per lot, per configuration.

	4.	 	[* * *]
	 
	5.	 	Once the Client has executed this Quote Agreement and initialed Notes and Comments and Terms
and Conditions, please mail the original [* * *] to:

Matthew LaFontaine

Controller

Bio-Concept Laboratories, Inc.

4 Tinkham Avenue, Suite 104

Derry, NH 03038

The
events described in this Quote Agreement shall not commence until such time as the
executed original Quote Agreement [* * *] received by Bio-Concept
Laboratories, Inc.

Client Initials: /s/ WS

4EX-10.2

 

Exhibit 10.2

Executive
Officers of
The Scotts Miracle-Gro Company

who are parties to form of

Employee Confidentiality, Noncompetition,

Nonsolicitation Agreement for employees

participating in The Scotts Company LLC

     Executive/Management Incentive Plan      

	 	 	 
	Name and Principal Position	 	Date of Employee Confidentiality,
	with The Scotts Miracle-Gro Company	 	Noncompetition, Nonsolicitation Agreement
	 
	 	 
	Christopher L. Nagel, Executive Vice President

	 	August 7, 2006
	 
	 	 
	David M. Aronowitz,
Executive Vice President, General Counsel and Corporate Secretary

	 	May 11, 2006
	 
	 	 
	Denise
S. Stump, Executive Vice President, Global
Human Resources

	 	August 8, 2006
	 
	 	 
	David
C. Evans,
Executive Vice President,
Chief Financial Officer

	 	May 20, 2006

- 7 -exv10w1

 

Exhibit 10.1

AMENDED AND RESTATED MANAGEMENT AGREEMENT

     THIS AMENDED AND RESTATED MANAGEMENT AGREEMENT (the “Agreement”), made as of the 23rd day of
August, 2006, is entered into by VistaCare, Inc., a Delaware corporation with its principal place
of business at 8125 North Hayden Road, Suite 300, Scottsdale, Arizona 85258 (the “Company”), and
Richard R. Slager, an individual residing at 30210 East 148th Street, Scottsdale, Arizona 85262
(the “Executive”).

Recitals:

     WHEREAS, the Executive is an executive officer of the Company; and

     WHEREAS, the Company and the Executive, by agreement made as of October 9, 2002 provided for
certain payments and benefits to the Executive in the event the Executive’s employment by the
Company is terminated under certain circumstances or there is a change in control of the Company;
and

     WHEREAS, the Company and the Executive wish to confirm the provisions of such October 9, 2002
agreement as amended herein.

     NOW, THEREFORE, in consideration of the premises and the mutual covenants
contained herein, the parties hereto agree as follows:

     1. Definitions. As used in this Agreement the following terms shall have the following
respective meanings:

     (a) “Board” means the Board of Directors of the Company.

     (b) “Cause” shall mean: (i) the Executive’s willful failure to attempt in good faith to follow
the legal written directions of the Board, which is not cured within ten (10) days following
receipt by the Executive of written notice from the Board specifying the details thereof, (ii) the
Executive’s conviction of a felony (other than a felony involving a traffic violation or as a
result of vicarious liability), (iii) the Executive’s commission of an act constituting fraud,
embezzlement, larceny or theft with regard to the Company that is of a material nature (other than
good faith expense account reimbursement disputes) or (iv) willful misconduct by the Executive with
regard to the Company that has a material adverse effect on the Company. For purposes of this
definition, no act, or failure to act, on the Executive’s part shall be considered “willful” unless
done or omitted to be done by him not in good faith and without reasonable belief that his action
or omission was in the best interests of the Company.

     (c) “Change in Control” means (i) the acquisition by a person, party or a group (within the
meaning of Section 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended) of
outstanding capital stock of the Company representing more than 50% of the combined voting power of
all voting securities of the Company entitled to vote generally in the election of directors,
excluding acquisitions from the Company, (ii) a change of a majority of the Board, without the
approval or consent of the members of the Board before such change, (iii) the acquisition of the
Company by means of a reorganization, merger, consolidation, recapitalization or asset sale, unless
the owners of the capital stock of the

1

 

Company immediately before such transaction continue to own, in substantially the same proportions
as before such transaction, capital stock of the acquiring or succeeding entity representing more
than 50% of the combined voting power of all voting securities of such acquiring or succeeding
entity entitled to vote generally in the election of directors, or (iv) the approval of a
liquidation or dissolution of the Company.

     (d) “Confidential Information” means all trade secrets and other information of a business,
financial, marketing, technical or other nature pertaining to the Company or any of its
subsidiaries or affiliates, including information of others that the Company or any of its
subsidiaries or affiliates has agreed to keep confidential; provided, that Confidential Information
shall not include any information that has entered or enters the public domain through no fault of
the Executive, was known by the Executive prior to the Executive’s affiliation with or employment
by the Company or which the Executive is required to disclose by legal process.

     (e) “Disability” means the failure of the Executive, due to physical or mental disability, to
perform the services reasonably contemplated by his position for a period of either (i) ninety (90)
consecutive days or (ii) one hundred twenty (120) days, whether or not consecutive, during any
360-day period.

     (f) “Good Reason” means any of the following events (unless consented to by the Executive in
writing): (i) a material diminution in the Executive’s duties, responsibilities or the assignment
to the Executive of duties or responsibilities that are inconsistent in a material and adverse way
with his then position; (ii) a reduction in the Executive’s base salary; (iii) a requirement by the
Company that the Executive’s principal place of work be moved to a location more than thirty-five
(35) miles away from Scottsdale, Arizona; or (iv) a change in the Executive’s title to a lesser title.

     (g) “Per-Share Equity Value” means (i) the total amount of cash and the fair market value of
all other property paid directly or indirectly by an acquiror to the Company and/or its equity
security holders in connection with a Sale of the Company, divided by (ii) the total number of
outstanding shares of the Company’s Class A Common Stock, $.01 par value per share (the “Common
Stock”), immediately before the closing of a Sale of the Company transaction, assuming the
conversion of all shares of capital stock convertible into the Company and the exercise of all
warrants, options and other rights to purchase the Common Stock. The value of any securities
issuable in connection with a Sale of the Company (whether debt or equity) freely tradable in an
established public market will be determined on the basis of the last closing price in such market
five (5) days prior to the consummation of the Sale of the Company (the “Valuation Date”), and the
value of securities not freely tradable (or having no established market) or other property will be
the fair market value of such securities or other property on such Valuation Date as determined in
good faith by the Board.

     (h) “Sale of the Company” means (i) the acquisition by a person, party or a group (within the
meaning of Section 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended) of
outstanding capital stock of the Company representing more than 50% of the combined voting power of
all voting securities of the Company entitled to vote generally in the election of directors,
excluding acquisitions from the Company, or (ii) the acquisition of the Company by means of a
reorganization, merger, consolidation, recapitalization or asset

2

 

sale, unless the owners of the capital stock of the Company immediately before such transaction
continue to own, in substantially the same proportions as before such transaction, capital stock of
the acquiring or succeeding entity representing more than 50% of the combined voting power of all
voting securities of such acquiring or succeeding entity entitled to vote generally in the election
of directors.

     2. Employment At-Will Acknowledgement. The Executive acknowledges and agrees that his
employment by the Company is “at-will” and as such may be terminated by the Company at any time,
with or without cause, subject to the provisions of this Agreement.

     3. Compensation Upon Termination of Employment Prior to Change in Control. If prior
to a Change in Control the Executive’s employment by the Company is terminated by the Company for
any reason other than Cause or the Executive’s death or Disability or is terminated by the
Executive for Good Reason, the Company shall:

     (a) pay to the Executive within five (5) days after the date of his employment termination all
accrued but unpaid salary, bonus and vacation pay, if any;

     (b) continue to pay to the Executive his then current salary in bi-weekly installments until
the first anniversary of his employment termination;

     (c) continue to provide the Executive until the first anniversary of
his employment termination date with the health and life insurance benefits he would have received
had his employment by the Company not terminated or substantially the equivalent coverage (or the
full value thereof in cash); and

     (d) promptly reimburse the Executive for any and all legal fees and
expenses incurred by him to enforce the provisions of this Agreement.

     4. Compensation Upon Termination of Employment After Change in Control. If within two
(2) years following a Change in Control the Executive’s employment by the Company is terminated for
any reason (including death, disability or voluntary resignation) other than by the Company for
Cause, the Company shall:

     (a) pay to the Executive within five (5) days after the date of his
employment termination all accrued but unpaid salary, bonus and vacation pay, if any;

     (b) pay to the Executive (or his estate, in the case of the Executive’s death) within thirty
(30) days after the date of his employment termination a lump sum amount equal to three times his
then current annual salary;

     (c) if such Change in Control does not result from a Sale of the Company prior to December 31,
2006 that would entitle the Executive to receive a Transaction Fee pursuant to Section 6 of this
Agreement, pay to the Executive (or his estate, in the case of the Executive’s death) within thirty
(30) days after the date of his employment termination a lump sum amount equal to the greater of
the Executive’s last earned bonus payment or target bonus payment for the year in which his
employment is terminated;

     (c) continue to provide the Executive for three (3) years after the date of his

3

 

employment termination with the health and life insurance benefits he would have received had
his employment by the Company not terminated or substantially the equivalent coverage (or the full
value thereof in cash); and

     (d) promptly reimburse the Executive for any and all legal fees and expenses incurred by him
to enforce the provisions of this Agreement.

     5. Acceleration of Option Vesting. Upon a Change in Control, regardless of
whether the Executive’s employment is terminated, the vesting of all restricted stock granted to
the Executive by the Company and of all options granted by the Company to the Executive to purchase
shares of the Company’s capital stock shall be accelerated in full.

     6. Transaction Fee. (a) If there is a Sale of the Company prior to December 31, 2006,
the Executive shall be entitled to a fee (a “Transaction Fee”) equal to the amount specified in the
table below corresponding to the date on which such transaction closes; provided, however, that no
Transaction Fee shall be payable if the Per-Share Equity Value is less than $5.00 (appropriately
adjusted for stock splits, combinations, stock dividends, recapitalizations and the like affecting
the Common Stock) or if the Executive is not employed by the Company on the closing date of such
transaction (other than as a result of being terminated without Cause by the Company (A) within six
(6) months prior to such closing date or (B) within twelve (12) months prior to such closing if a
definitive agreement with respect to the transaction had been executed at the time of such
termination).

	 	 	 	 	 
	9/30/02 - 12/31/02
	 	$	5,000,000	 
	1/1/03 - 12/31/03
	 	$	4,000,000	 
	1/1/04 - 12/31/04
	 	$	3,000,000	 
	1/1/05 - 12/31/05
	 	$	2,000,000	 
	1/1/06 - 12/31/06
	 	$	1,000,000	 

     (b) If the terms of a transaction constituting a Sale of the Company provide for escrowed,
contingent or installment payments, the portion of the Transaction Fee relating to such payments
shall be paid if and when such payments are actually received by the security holders and/or the
Company.

     (c) The Transaction Fee shall be payable in the same form and in the same proportion as the
consideration received by the Company and/or its security holders in connection with the Sale of
the Company.

     7. Confidentiality. (a) The Executive will not at any time, directly or indirectly,
disclose or divulge, except as required in connection with the performance of the Executive’s
duties for the Company, any Confidential Information acquired by the Executive during or in
connection with the Executive’s affiliation with or employment by the Company.

     (b) The Executive shall make no use whatsoever, directly or indirectly, of any Confidential
Information, except as required in connection with the performance of the Executive’s duties for
the Company.

     (c) Upon the Company’s request at any time and for any reason, the Executive shall immediately
deliver to the Company all materials (including all copies) in the

4

 

Executive’s possession which contain or relate to Confidential Information.

     8. Non-competition and Non-solicitation. The Executive agrees that prior to the
termination of the Executive’s employment with the Company for whatever reason, and thereafter for
two years:

     (a) the Executive will not directly or indirectly, individually or as a consultant to, or
employee, officer, director, stockholder, partner or other owner of or participant in any business
entity other than the Company, engage in or assist any other person to engage in the business of
providing hospice services in competition with the Company or any of its subsidiaries; and

     (b) the Executive will not directly or indirectly, individually or as a consultant to, or
employee, officer, director, stockholder, partner or other owner of or participant in any business
entity other than the Company, solicit or hire from the Company or any of its subsidiaries or
affiliates, or otherwise materially interfere with the business relationship of the Company or any
of its subsidiaries or affiliates with, (i) any person who is, or was within the six-month period
immediately prior to the termination of the Executive’s employment with the Company, employed by or
associated with the Company or any of its subsidiaries or affiliates or (ii) any person or entity
who is, or was within the six-month period immediately prior to the termination of the Executive’s
employment with the Company, a patient referral source for the Company or any of its subsidiaries
or affiliates. Notwithstanding anything contained herein to the contrary, the Executive shall not
be prohibited from soliciting or hiring Stephen Lewis, Rob Rossi or Ben Smith.

     9. Remedies. Without limiting the remedies available to the Company, the
Executive acknowledges that a breach of any of the covenants contained in Sections 7 and 8 herein
could result in irreparable injury to the Company for which there might be no adequate remedy at
law, and that, in the event of such a breach or threat thereof, the Company shall be entitled to
obtain a temporary restraining order and/or a preliminary injunction and a permanent injunction
restraining the Executive from engaging in any activities prohibited by Sections 7 and 8 herein or
such other equitable relief as may be required to enforce specifically any of the covenants of
Sections 7 and 8 herein. The foregoing provisions of Sections 7 and 8 herein shall survive the
termination of this Agreement and shall continue thereafter in full force and effect in accordance
with the terms of Sections 7 and 8 herein for the periods of time contemplated thereby.

     10. Release. It shall be a condition of the Company’s obligation to make the payments
and provide the benefits contemplated by Sections 3 and 4 that the Executive execute and deliver to
the Company a release in form and substance satisfactory to the Company pursuant to which the
Executive unconditionally and irrevocably waives, relinquishes and forever releases and discharges
the Company and its officers, directors, shareholders, employees, agents, subsidiaries, affiliates,
predecessors, successors and assigns (collectively, the “Company Indemnitees”) from any and all
claims, duties, causes of actions, demands, obligations, liabilities, rights, damages (including
business, punitive or exemplary damages) of any kind or nature whether existing or contingent, then
known or unknown, asserted or unasserted, whether in law, equity and administrative proceeding that
the Executive then has or ever had against the Company Indemnitees since the beginning of the world
through the date thereof including, but not limited to, any and all matters related in any

5

 

way to the Executive’s employment with or separation from the Company, as well as claims under the
Employee Retirement Income Security Act of 1974, Title VII of the Civil Rights Act of 1964, the Age
Discrimination in Employment Act, the Americans with Disabilities Act, any claim based on state
anti-discrimination laws, any claim for wrongful discharge, and any alleged violation of public
policy, contract or tort law, or any other federal, state, or local law; provided, however, that
such release shall not apply to the terms and conditions of this Agreement, which shall remain
valid and enforceable.

     11. Arbitration. In the case of any dispute under this Agreement, the Executive may
initiate binding arbitration in Phoenix, Arizona, before the American Arbitration Association by
serving a notice to arbitrate upon the Company or, at the Executive’s election, institute judicial
proceedings, in either case within 90 days of the effective date of his termination or, if later,
his receipt of notice of termination, or such longer period as may be reasonably necessary for the
Executive to take such action if illness or incapacity should impair his taking such action within
the 90-day period. The Company shall not have the right to initiate binding arbitration, and agrees
that upon the initiation of binding arbitration by Executive pursuant to this Section 11 the
Company shall cause to be dismissed any judicial proceedings it has brought against the Executive
relating to this Agreement. The Company authorizes the Executive from time to time to retain
counsel of his choice to represent the Executive in connection with any and all actions,
proceedings, and/or arbitration, whether by or against the Company or any director, officer,
shareholder, or other person affiliated with the Company, which may affect Executive’s rights under
this Agreement. The Company agrees (i) to pay the fees and expenses of such counsel, (ii) to pay
the cost of such arbitration and/or judicial proceeding, and (iii) to pay interest to the Executive
on all amounts owed to the Executive under this Agreement during any period of time that such
amounts are withheld pending arbitration and/or judicial proceedings. Such interest will be at the
base rate as announced from time to time by HealthcareBusiness Credit Corporation, or its
successor.

     12. Binding on Successors. If the Company is at any time before or after a
Change in Control merged or consolidated into or with any other corporation or other entity
(whether or not the Company is the surviving entity), or if substantially all of the assets thereof
are transferred to another corporation or other entity, the provisions of this Agreement will be
binding upon and inure to the benefit of the corporation or other entity resulting from such merger
or consolidation or the acquirer of such assets, and this Section 12 will apply in the event of any
subsequent merger or consolidation or transfer of assets. In the event of any such merger,
consolidation or sale of assets, references to the Company in this Agreement shall unless the
context suggests otherwise be deemed to include the entity resulting from such merger or
consolidation or the acquirer of such assets of the Company.

     13. Withholding. All payments required to be made by the Company hereunder to the
Executive or his dependents, beneficiaries, or estate will be subject to the withholding of such
amounts relating to tax and/or other payroll deductions as may be required by law.

     14. No Duty to Mitigate. There shall be no requirement on the part of the
Executive to seek other employment or otherwise mitigate damages in order to be entitled to the
full amount of any payments and benefits to which the Executive is entitled under this Agreement,
and the amount of such payments and benefits shall not be reduced by any compensation or benefits
received by the Executive from other employment.

6

 

     15. No Contract of Employment. Nothing contained in this Agreement shall
be construed as a contract of employment between the Company and the Executive,or as a right of the
Executive to continue in the employ of the Company, or as a limitation of the right of the Company
to discharge the Executive with or without Cause; provided that the Executive shall have the right
to receive upon termination of his employment the payments and benefits provided in this Agreement.

     16. No Other Severance. Payments made by the Company pursuant to this
Agreement shall be in lieu of severance payments, if any, which might otherwise be available to the
Executive.

     17. Successors and Assigns. The provisions of this Agreement, shall be
binding upon and shall inure to the benefit of the Executive, his executors, administrators, legal
representatives, and assigns, and the Company and its successors.

     18. No Set-off. The Company shall have no right of set-off or counterclaims, in
respect of any claim, debt, or obligation, against any payments to the Executive, his dependents,
beneficiaries, or estate provided for in this Agreement.

     19. Assignment. No right or interest to or in any payments shall be assignable by the
Executive; provided, however, that this provision shall not preclude him from designating one or
more beneficiaries to receive any amount that may be payable after his death and shall not preclude
the legal representative of his estate from assigning any right hereunder to the person or persons
entitled thereto under his will or, in the case of intestacy, to the person or persons entitled
thereto under the laws of intestacy applicable to his estate. The term “beneficiaries” as used in
this Agreement shall mean a beneficiary or beneficiaries so designated to receive any such amount,
or if no beneficiary has been so designated, the legal representative of the Executive’s estate. No
right, benefit, or interest hereunder, shall be subject to anticipation, alienation, sale,
assignment, encumbrance, charge, pledge, hypothecation, or set-off in respect of any claim, debt,
or obligation, or to execution, attachment, levy, or similar process, or assignment by operation of
law. Any attempt, voluntary or involuntary, to effect any action specified in the immediately
preceding sentence shall, to the full extent permitted by law, be null, void, and of no effect.

     20. Notices. All notices required or permitted under this Agreement shall be in
writing and shall be deemed effective upon personal delivery or upon deposit in the United States
Post Office, by registered or certified mail, postage prepaid, addressed to the other party at the
address shown above, or at such other address or addresses as either party shall designate to the
other in accordance with this Section 20.

     21. Entire Agreement. This Agreement constitutes the entire agreement
between the parties and supersedes all prior agreements and understandings, whether written or
oral, relating to the subject matter of this Agreement, including without limitation that certain
letter agreement between the Company and the Executive dated May 24, 2001.

     22. Amendment. This Agreement may be amended or modified only by a written instrument
executed by both the Company and the Executive.

     23. Governing Law. This Agreement shall be construed, interpreted and

7

 

enforced in accordance with the laws of the State of Arizona.

     24. Miscellaneous.

     (a) No delay or omission by the Company in exercising any right
under this Agreement shall operate as a waiver of that or any other right. A waiver or consent
given by the Company on any one occasion shall be effective only in that instance and shall not be
construed as a bar or waiver of any right on any other occasion.

     (b) The captions of the sections of this Agreement are for convenience of reference only and
in no way define, limit or affect the scope or substance of any section of this Agreement.

     (c) In case any provision of this Agreement shall be invalid, illegal or otherwise
unenforceable, the validity, legality and enforceability of the remaining provisions shall in no
way be affected or impaired thereby.

     IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of
the day and year set forth above.

	 	 	 	 	 	 	 
	 	 	VISTACARE, INC.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	 /s/ David W. Elliot	 	 
	 

	 	 	 	 	 	 
	 

	 	Title:	 	 President	 	 
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 
	 	 	 	 /s/ Richard R. Slager	 	 
	 	 	 	 	 
	 	 	            Richard R. Slager
	 	 

8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00110-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00110-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00110-of-00352.parquet"}]]